These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 27530328)
1. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells. Shi Y; Daniels-Wells TR; Frost P; Lee J; Finn RS; Bardeleben C; Penichet ML; Jung ME; Gera J; Lichtenstein A Cancer Res; 2016 Oct; 76(19):5822-5831. PubMed ID: 27530328 [TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction. Lee J; Shi Y; Vega M; Yang Y; Gera J; Jung ME; Lichtenstein A Bioorg Med Chem Lett; 2017 Oct; 27(20):4714-4724. PubMed ID: 28916338 [TBL] [Abstract][Full Text] [Related]
3. A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity. Vega MI; Shi Y; Frost P; Huerta-Yepez S; Antonio-Andres G; Hernandez-Pando R; Lee J; Jung ME; Gera JF; Lichtenstein A Mol Cancer Ther; 2019 Oct; 18(10):1822-1831. PubMed ID: 31395691 [TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor β integrates Smad 3 to mechanistic target of rapamycin complexes to arrest deptor abundance for glomerular mesangial cell hypertrophy. Das F; Ghosh-Choudhury N; Bera A; Dey N; Abboud HE; Kasinath BS; Choudhury GG J Biol Chem; 2013 Mar; 288(11):7756-7768. PubMed ID: 23362262 [TBL] [Abstract][Full Text] [Related]
5. TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression. Das F; Bera A; Ghosh-Choudhury N; Abboud HE; Kasinath BS; Choudhury GG PLoS One; 2014; 9(10):e109608. PubMed ID: 25333702 [TBL] [Abstract][Full Text] [Related]
6. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Peterson TR; Laplante M; Thoreen CC; Sancak Y; Kang SA; Kuehl WM; Gray NS; Sabatini DM Cell; 2009 May; 137(5):873-86. PubMed ID: 19446321 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. Zhang HR; Chen JM; Zeng ZY; Que WZ J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505 [TBL] [Abstract][Full Text] [Related]
8. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro. Zhang H; Chen J; Zeng Z; Que W; Zhou L Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641 [TBL] [Abstract][Full Text] [Related]
9. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Yang Y; Bardeleben C; Frost P; Hoang B; Shi Y; Finn R; Gera J; Lichtenstein A Genes Cancer; 2014 Nov; 5(11-12):407-19. PubMed ID: 25568666 [TBL] [Abstract][Full Text] [Related]
10. Akt2 causes TGFβ-induced deptor downregulation facilitating mTOR to drive podocyte hypertrophy and matrix protein expression. Das F; Ghosh-Choudhury N; Lee DY; Gorin Y; Kasinath BS; Choudhury GG PLoS One; 2018; 13(11):e0207285. PubMed ID: 30444896 [TBL] [Abstract][Full Text] [Related]
11. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141 [TBL] [Abstract][Full Text] [Related]
12. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Gera J; Lichtenstein A Leuk Lymphoma; 2011 Oct; 52(10):1857-66. PubMed ID: 21599581 [TBL] [Abstract][Full Text] [Related]
13. Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma. Yen CH; Lu YC; Li CH; Lee CM; Chen CY; Cheng MY; Huang SF; Chen KF; Cheng AL; Liao LY; Lee YH; Chen YM Mol Med; 2012 Mar; 18(1):286-96. PubMed ID: 22160218 [TBL] [Abstract][Full Text] [Related]
14. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Cirstea D; Santo L; Hideshima T; Eda H; Mishima Y; Nemani N; Mahindra A; Yee A; Gorgun G; Hu Y; Ohguchi H; Suzuki R; Cottini F; Guichard SM; Anderson KC; Raje N Mol Cancer Ther; 2014 Nov; 13(11):2489-500. PubMed ID: 25172964 [TBL] [Abstract][Full Text] [Related]
15. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. Que W; Chen J; Chuang M; Jiang D APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676 [TBL] [Abstract][Full Text] [Related]
16. Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation. Vega M; Chen Y; Shi Y; Gera J; Lichtenstein A J Biol Chem; 2022 Apr; 298(4):101750. PubMed ID: 35216969 [TBL] [Abstract][Full Text] [Related]
17. Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells. Catena V; Bruno T; De Nicola F; Goeman F; Pallocca M; Iezzi S; Sorino C; Cigliana G; Floridi A; Blandino G; Fanciulli M Oncotarget; 2016 Oct; 7(43):70546-70558. PubMed ID: 27655709 [TBL] [Abstract][Full Text] [Related]
18. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Hoang B; Frost P; Shi Y; Belanger E; Benavides A; Pezeshkpour G; Cappia S; Guglielmelli T; Gera J; Lichtenstein A Blood; 2010 Nov; 116(22):4560-8. PubMed ID: 20686120 [TBL] [Abstract][Full Text] [Related]